Beta Drugs Limited (NSE:BETA)
India
· Delayed Price · Currency is INR 1,696.15
-19.95 (-1.16%)
At close: Mar 10, 2025
Beta Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 3,347 | 2,957 | 2,271 | 1,838 | 1,161 | 908.06 | Upgrade
|
| Revenue Growth (YoY) | 30.77% | 30.21% | 23.54% | 58.31% | 27.88% | 37.73% | Upgrade
|
| Cost of Revenue | 2,012 | 1,814 | 1,297 | 1,123 | 722.76 | 548.41 | Upgrade
|
| Gross Profit | 1,336 | 1,143 | 974.47 | 714.89 | 438.46 | 359.65 | Upgrade
|
| Selling, General & Admin | 318.54 | 276.67 | 242.78 | 169.97 | 121.32 | 109.79 | Upgrade
|
| Other Operating Expenses | 358.37 | 267.57 | 197.32 | 117.94 | 69.27 | 69.37 | Upgrade
|
| Operating Expenses | 777.43 | 642.07 | 544.2 | 360.45 | 259.33 | 216.75 | Upgrade
|
| Operating Income | 558.12 | 501.31 | 430.27 | 354.44 | 179.14 | 142.9 | Upgrade
|
| Interest Expense | -31.34 | -26.77 | -22.8 | -17.89 | -22.2 | -22.94 | Upgrade
|
| Interest & Investment Income | 10.84 | 10.84 | 6.63 | 4.52 | 3.34 | 2.43 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.84 | 0.84 | -3.09 | 0.43 | -0 | -0.41 | Upgrade
|
| Other Non Operating Income (Expenses) | 11.02 | 1.33 | -0.44 | 1.51 | -0.74 | -2.06 | Upgrade
|
| EBT Excluding Unusual Items | 549.48 | 487.54 | 410.57 | 343.01 | 159.54 | 119.91 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.03 | -0.2 | Upgrade
|
| Pretax Income | 549.48 | 487.54 | 410.57 | 343.01 | 159.51 | 119.72 | Upgrade
|
| Income Tax Expense | 139.48 | 123.17 | 103.38 | 94.74 | 42.26 | 25.57 | Upgrade
|
| Net Income | 410 | 364.37 | 307.19 | 248.28 | 117.25 | 94.15 | Upgrade
|
| Net Income to Common | 410 | 364.37 | 307.19 | 248.28 | 117.25 | 94.15 | Upgrade
|
| Net Income Growth | 17.96% | 18.62% | 23.73% | 111.76% | 24.53% | 17.11% | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 9 | Upgrade
|
| Shares Change (YoY) | -0.01% | - | - | - | 1.39% | 9.62% | Upgrade
|
| EPS (Basic) | 42.65 | 37.90 | 31.95 | 25.82 | 12.20 | 9.93 | Upgrade
|
| EPS (Diluted) | 42.65 | 37.90 | 31.95 | 25.82 | 12.20 | 9.93 | Upgrade
|
| EPS Growth | 17.98% | 18.62% | 23.74% | 111.72% | 22.82% | 6.83% | Upgrade
|
| Free Cash Flow | 134.53 | 193.15 | 51.71 | 102 | 128.44 | -68.84 | Upgrade
|
| Free Cash Flow Per Share | 13.99 | 20.09 | 5.38 | 10.61 | 13.36 | -7.26 | Upgrade
|
| Gross Margin | 39.90% | 38.66% | 42.91% | 38.89% | 37.76% | 39.61% | Upgrade
|
| Operating Margin | 16.67% | 16.95% | 18.94% | 19.28% | 15.43% | 15.74% | Upgrade
|
| Profit Margin | 12.25% | 12.32% | 13.53% | 13.51% | 10.10% | 10.37% | Upgrade
|
| Free Cash Flow Margin | 4.02% | 6.53% | 2.28% | 5.55% | 11.06% | -7.58% | Upgrade
|
| EBITDA | 651.66 | 592.16 | 534.37 | 426.98 | 247.87 | 180.48 | Upgrade
|
| EBITDA Margin | 19.47% | 20.02% | 23.53% | 23.23% | 21.35% | 19.88% | Upgrade
|
| D&A For EBITDA | 93.55 | 90.85 | 104.1 | 72.54 | 68.74 | 37.59 | Upgrade
|
| EBIT | 558.12 | 501.31 | 430.27 | 354.44 | 179.14 | 142.9 | Upgrade
|
| EBIT Margin | 16.67% | 16.95% | 18.94% | 19.28% | 15.43% | 15.74% | Upgrade
|
| Effective Tax Rate | 25.38% | 25.26% | 25.18% | 27.62% | 26.50% | 21.36% | Upgrade
|
| Revenue as Reported | 3,371 | 2,971 | 2,279 | 1,846 | 1,166 | 912.16 | Upgrade
|
| Advertising Expenses | - | 14.57 | 12.57 | 8 | 6.74 | 6.85 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.